Premium
Comparison between PD‐1/PD‐L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
Author(s) -
Wu Yingcheng,
Lin Lifeng,
Shen Yanting,
Wu Huiqun
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31733
Subject(s) - pembrolizumab , atezolizumab , nivolumab , medicine , bayesian probability , oncology , credible interval , hazard ratio , random effects model , meta analysis , adverse effect , lung cancer , confidence interval , cancer , computer science , artificial intelligence , immunotherapy